Recent trend of the pathophysiology and treatment of pituitary adenomas

Brain and Nerve

Volumn 61, Issue 8, 2009, Pages 957-962

  Matsuno, Akira ^a  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

Author keywords

Cabergoline; Octreotide; Pegvisomant; Pituitary adenoma; Transsphenoidal surgery

Indexed keywords

CABERGOLINE; CORTICOTROPIN RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR; HYPOTHALAMUS HORMONE; OCTREOTIDE; PEGVISOMANT; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; ERGOLINE DERIVATIVE; HORMONE RECEPTOR; HUMAN GROWTH HORMONE; NEUROPEPTIDE RECEPTOR; SOMATOTROPIN RELEASING HORMONE RECEPTOR;

ADENOMA; ADULT; CELL DIFFERENTIATION; ENDOSCOPIC SURGERY; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE SECRETING ADENOMA; HORMONE SUBSTITUTION; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; HYPOPHYSIS ADENOMA; HYPOPHYSIS CELL; INTERMETHOD COMPARISON; MICROSURGERY; POSTOPERATIVE COMPLICATION; PROLACTINOMA; QUALITY OF LIFE; REVIEW; SURGICAL APPROACH; SURGICAL TECHNIQUE; TRANSSPHENOIDAL SURGERY; GENETICS; HYPOPHYSIS TUMOR; INCIDENTAL FINDING; METHODOLOGY; NEUROSURGERY;

ADENOMA; ANTINEOPLASTIC AGENTS; CORTICOTROPIN-RELEASING HORMONE; DACARBAZINE; ERGOLINES; GROWTH HORMONE-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; HYPOTHALAMIC HORMONES; INCIDENTAL FINDINGS; NEUROSURGICAL PROCEDURES; OCTREOTIDE; PITUITARY NEOPLASMS; PROLACTINOMA; RECEPTORS, NEUROPEPTIDE; RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE;

EID: 69549108450     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Asa SL, Ezzat S: Molecular determinants of pituitary cytodifferentiation. Pituitary 1: 159-168, 1999
2. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjöld M: Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332: 85-87, 1988 (Pubitemid 18083554)
3. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, et al: Mutations of the genes encoding the protein kinase A type 1-alpha regulatory subunit in patients with the Carney complex. Nat Genet 26: 89-92, 2000 (Pubitemid 30692864)
4. Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, et al: Two G protein oncogenes in human endocrine tumors. Science 249: 655-659, 1990 (Pubitemid 20259082)
5. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, et al: The role of the AIP gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 93: 2390-2401, 2008
6. Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T, et al: The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH secreting adenomas. Clin Endocrinol (Oxf) 66: 499-502, 2007 (Pubitemid 46434927)
7. Wakabayashi I, Inokuchi K, Hasegawa O, Sugihara H, Minami S: Expression of growth hormone (GH)-releasing factor gene in GH-producing pituitary adenoma. J Clin Endocrinol Metab 74: 357-361, 1992
8. Levy A, Lightman SL: Growth hormone-releasing hormone transcripts in human pituitary adenomas. J Clin Endocrinol Metab 74: 1474-1476, 1992
9. Joubert (Bression) D, Benlot C, Lagoguey A, Garnier P, Brandi AM, et al: Normal and growth hormone (GH)-secreting adenomatous human pituitaries release somatostatin and GH-releasing hormone. J Clin Endocrinol Metab 68: 572-577, 1989 (Pubitemid 19081431)
10. Thapar K, Kovacs K, Stefaneanu L, Scheithauer B, Killinger DW, et al: Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior. Am J Pathol 151: 769-784, 1997 (Pubitemid 27385609)
11. Matsuno A, Katakami H, Nagashima T, Teramoto A, Osamura RY, et al: Growth hormone-releasing hormone (GHRH) expression in pituitary somatotroph adenomas, studied by immunohistochemistry and in situ hybridization using catalyzed signal amplification system. Hum Pathol 31: 789-794, 2000 (Pubitemid 30480448)
12. Matsuno A, Katakami H, Sanno N, Ogino Y, Osamura RY, et al: Pituitary somatotroph adenoma producing growth hormone-releasing hormone (GHRH) with an elevated plasma GHRH concentration: A model case for autocrine and paracrine regulation of growth hormone secretion by GHRH. J Clin Endocrinol Metab 84: 3241-3247, 1999 (Pubitemid 30646951)
13. Xu B, Sano T, Yamada S, Li CC, Hirokawa M: Expression of corticotropin-releasing hormone messenger ribonucleic acid in human pituitary corticotroph adenomas associated with proliferative potential. J Clin Endocrinol Metab 85: 1220-1225, 2000 (Pubitemid 32269376)
14. Molitch ME: Evaluation and treatment of the patient with a pituitary incidentaloma. J Clin Endocrinol Metab 80: 3-6, 1995
15. Matsuno A, Sasaki T, Saito N, Mochizuki T, Fujima-ki T, et al: Transcavernous surgery; an effective treatment for pituitary macroadenomas. Eur J Endocrinol (Acta Endocrinol) 133: 156-165, 1995
16. Ono M, Miki N, Kawamata T, Makino R, Amano K, et al: Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93: 4721-4727, 2008
17. AACE Acromegaly Guidelines Task Force: American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract 10: 213-225, 2004
18. Selvarajah D, Webster J, Ross R, Newell-Price J: Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 152: 569-574, 2005 (Pubitemid 40575802)
19. Cozzi R, Attanasio R, Lodrini S, Lasio G: Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf). 61: 209-215, 2004 (Pubitemid 39093116)
20. Stewart PM. Pegvisomant: an advance in clinical efficacy in acromegaly. Eur J Endocrinol 148 Suppl 2: S27-S32, 2003 (Pubitemid 36528167)
21. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, et al: Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90: 5627-5631, 2005 (Pubitemid 41415468)
22. Gibson S, Ray DW, Crosby SR, Dornan TL, Jennings AM, et al: Impaired processing of proopiomelanocortin in corticotroph macroadenomas. J Clin Endocrinol Metab 81: 497-502, 1996 (Pubitemid 26055653)
23. Yamakita N, Murai T, Kawamura S, Teramachi H, Matsuhisa T, et al: High molecular weight corticotropin measured with immunoradiometric assay in a patient with asymptomatic pituitary corticotropinoma. Endocr J 46: 563-571, 1999 (Pubitemid 29436742)
24. Yamakita N, Murai T, Oki Y, Matsuhisa T, Hirata T, et al: Adrenal insufficiency after incomplete resection of pituitary macrocorticotropinoma of Cushing's disease: role of high molecular weight ACTH. Endocr J 48: 43-51, 2001 (Pubitemid 32230384)
25. Matsuno A, Okazaki R, Oki Y, Nagashima T: Secretion of high-molecular-weight adrenocorticotropic hormone from a pituitary adenoma in a patient without Cushing stigmata. J Neurosurg 101: 880-883, 2004 (Pubitemid 39430988)
26. Matsuno A, Ogino Y, Katayama H, Osamura RY, Nagashima T: Identification of a silent pituitary somatotropic adenoma based on a paradoxical response of growth hormone on a thyrotropin-releasing hormone or gonadotropin-releasing hormone provocation test. Am J Obstet Gynecol 184: 286-288, 2001 (Pubitemid 32206973)
27. Matsuno A, Itoh J, Itoh Y, Osamura RY, Katayama H, et al: Histopathological analyses of silent pituitary somatotroph adenomas using immunohistochemistry, in situ hybridization and confocal laser scanning microscopic observation. Pathol Res Pract 197: 13-20, 2001 (Pubitemid 32110895)
28. Neff LM, Weil M, Cole A, Hedges TR, Shucart W, et al: Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10: 81-86, 2007 (Pubitemid 46562811)
29. Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, et al: Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol 38: 185-189, 2007 (Pubitemid 44880216)
30. Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, et al: Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105: 621-626, 2006 (Pubitemid 44525896)
31. Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, et al: Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65: 552-553, 2006 (Pubitemid 44414285)
32. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP: Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7: 518-520, 2006 (Pubitemid 43796152)